| Name | BGT226 |
| Description | BGT226 (NVP-BGT226) is a novel dual PI3K/mTOR inhibitor, targeting PI3K α, β, and γ with IC50 values of 4 nM, 63 nM, and 38 nM, respectively. |
| In vitro | Growth inhibition experiment showed that BGT226 had antitumor activity. BGT226 significantly inhibited cell growth with IC50 < 20 nM. BGT226 also induced cancer cell apoptosis at nanomolar concentration, IC50 ≤ 25 nM[1][2][3]. |
| In vivo | BGT226 significantly delayed tumor growth on the transplanted tumor animal model. This effect was dose-dependent, accompanied by inhibition of p-p70 S6 kinase cytoplasmic expression and autophagy body formation[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 65 mg/mL (121.6 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (1.87 mM), Sonication is recommended.
|
| Keywords | PI3Kγ | PI3Kβ | PI3Kα | PI3K | NVP-BGT-226 | NVP-BGT 226 | mTOR | Mammalian target of Rapamycin | BGT-226 | BGT226 | BGT 226 | Autophagy |
| Inhibitors Related | Stavudine | Aceglutamide | Hemin | Tamoxifen | Cysteamine hydrochloride | Guanidine hydrochloride | Hydroxychloroquine | Enzalutamide | Paeonol | Naringin | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Hematonosis Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |